TY - JOUR
T1 - Drug interaction between Bortezomib and tuberculosis treatment
T2 - A case report
AU - Cuny, Pascale
AU - Marfaing-Koka, Anne
AU - Lottmann, Marion
AU - Rieutord, André
AU - Barbault-Foucher, Severine
PY - 2014/1/1
Y1 - 2014/1/1
N2 - An adult patient was diagnosed with plasmacytoma and monoclonal gammopathy. An increase in IgG λ and myeloma stage IIIa without cytogenetic abnormalities was found. The patient was treated with dexamethasone, bortezomib and pegylated liposomal doxorubicin. A decrease in monoclonal protein was observed during the first four cycles of chemotherapy. Isoniazid and rifampicin were introduced following suspected tuberculosis. Then, an increase in monoclonal gammopathy led to the combination of lenalidomide and chemotherapy. The persistent increase in the monoclonal component suggested a possible interaction between rifampicin and bortezomib. Tuberculosis treatment was stopped and a decrease in monoclonal protein during subsequent courses and regression of lesions on CT scan images confirmed this interaction to be likely. To our knowledge, this is the first report of concomitant administration of bortezomib with rifampicin. Therefore, a potential interaction between bortezomib and rifampicin should be anticipated during concomitant administration in the future.
AB - An adult patient was diagnosed with plasmacytoma and monoclonal gammopathy. An increase in IgG λ and myeloma stage IIIa without cytogenetic abnormalities was found. The patient was treated with dexamethasone, bortezomib and pegylated liposomal doxorubicin. A decrease in monoclonal protein was observed during the first four cycles of chemotherapy. Isoniazid and rifampicin were introduced following suspected tuberculosis. Then, an increase in monoclonal gammopathy led to the combination of lenalidomide and chemotherapy. The persistent increase in the monoclonal component suggested a possible interaction between rifampicin and bortezomib. Tuberculosis treatment was stopped and a decrease in monoclonal protein during subsequent courses and regression of lesions on CT scan images confirmed this interaction to be likely. To our knowledge, this is the first report of concomitant administration of bortezomib with rifampicin. Therefore, a potential interaction between bortezomib and rifampicin should be anticipated during concomitant administration in the future.
UR - http://www.scopus.com/inward/record.url?scp=84901290092&partnerID=8YFLogxK
U2 - 10.1136/ejhpharm-2013-000345
DO - 10.1136/ejhpharm-2013-000345
M3 - Article
AN - SCOPUS:84901290092
SN - 2047-9956
VL - 21
SP - 167
EP - 169
JO - European Journal of Hospital Pharmacy
JF - European Journal of Hospital Pharmacy
IS - 3
ER -